ProCE Banner Activity

Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Podcast Episodes

In this podcast, Helena Yu, MD, discusses recent advances in the field of antibody–drug conjugates and the current rationale for targeting HER3 for treatment of non-small-cell lung cancer.

Released: December 26, 2023

Share

Faculty

Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu

Helena Yu, MD

Associate Attending
Research Director of Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Rebecca S. Heist, MD, MPH: consultant/advisor: AstraZeneca, Claim, Daichii Sankyo, Lilly, Novartis, Regeneron, Sanofi.

Helena Yu, MD

Associate Attending
Research Director of Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: AstraZeneca, Black Diamond, Blueprint Medicine, Cullinan, Daiichi Sankyo, Taiho, Takeda.